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a b s t r a c t
The use of CO2 laser has become a routine procedure for the treatment of oral leukoplakia. In this
retrospective study, we evaluated 65 patients with oral leukoplakia treated with CO2 laser vaporization.
The main location was the tongue (n ¼ 21/65, 32.3%). The initial biopsy showed mild/moderate dysplasia
in almost half the patients (n ¼ 29, 44.6%) and hyperplasia without dysplasia in around a third of the
patients (n ¼ 21, 32.3%). The recurrence and malignant transformation rates were 33.8% (n ¼ 22) and
15.4% (n ¼ 10), respectively. The follow-up mean (standard deviation) was 15.0 (10.6) months. The
procedure-related complications rate was 7.7% (n ¼ 5). The KaplaneMeier curves for time to recurrence
showed differences only for gingiva lesions compared to tongue lesions (log rank, p ¼ 0.032). Malignant
leukoplakia transformation is independent of treatment, although it seems advisable to treat leukoplakia
with or without dysplasia.
© 2015 Published by Elsevier Ltd on behalf of European Association for Cranio-Maxillo-Facial Surgery.
1. Introduction
The World Health Organization (WHO) ﬁrst deﬁned oral leu-
koplakia as a white patch or plaque that could not be characterized
clinically or pathologically as any other disease (Axell et al., 1996).
At a workshop coordinated by the WHO in 2005, “potentially ma-
lignant disorder” was the preferred terms, with the working group
agreeing that the term leukoplakia should be used to recognize
“white plaques of questionable risk having excluded (other) known
diseases or disorders that carry no increased risk for cancer”
(Warnakulasuriya et al., 2007). Prevalence of oral leukoplakia is
reported to be approximately 2% (Petti, 2003; Brouns et al., 2013a,
2013b) and the annual malignant transformation rate is estimated
to be between 0.13% and 17.5% (Deppe et al., 2012; Kumar et al.,
2013; Brouns et al., 2014). Leukoplakia is considered to be the
most commonpremalignant lesion of the oral cavity; its occurrence
is related to smoking, with alcohol as an independent factor. The
role played by human papilloma virus is currently unknown (Van
der Waal, 2009). Risk factors associated with malignant leukopla-
kia transformation are: female gender, longer duration, non-
smokers, location on the tongue, size >200mm2, nonhomogeneous
type and presence of Candida albicans, or epithelial dysplasia (Van
derWaal, 2009, Ho et al., 2013). Head and neck cancers are the sixth
most common cancer worldwide and are considered an important
public health problem because of the poor prognosis and associated
high morbidity and mortality (Jerjes et al., 2011).
Incisional biopsy and histopathological examination are the
gold standard in diagnosis. Early detection of oral lesions increases
survival rates; hence, early and minimally invasive treatment
would be indicated for those patients who would be expected to
have low recurrence rates (Deppe et al., 2012; Brouns et al., 2013a;
Kumar et al., 2013). Several treatments have been suggested in the
literature, including surgery, electrosurgery, cryosurgery, topical
agents (bleomycin, vitamin A), systemic agents (b-carotene, lyco-
pene, retinoids), CO2 laser and photodynamic treatment, although
surgery and CO2 laser are most frequently used. There is still no
evidence that treatment prevents malignant transformation,
although it seems advisable to treat oral leukoplakia with or
without dysplasia (Horch et al., 1986; Chandu and Smith, 2005; Van
der Waal, 2009; Santos et al., 2010; Yang et al., 2011; Song and
Franco, 2011; Brouns et al., 2014) Q1.
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New technologies and improvements in oral and maxillofacial
surgery and especially in laser surgery prove less invasive andmore
comfortable for patients. The use of CO2 laser is becoming
increasingly common in the treatment of oral leukoplakia and
malignant tumours, with outcomes, advantages and disadvantages
fully reported in the literature (Chandu and Smith, 2005;
Escribano-Bermejos and Bascones-Martínez, 2009; Yang et al.,
2011; Deppe et al., 2012; Goodson et al., 2012). CO2 laser can be
used for both excision and vaporization. For vaporization, preferred
for large lesions, a prior biopsy is necessary (Chandu and Smith,
2005; Santos et al., 2010; Deppe et al., 2012; Brouns et al., 2013a,
2014). Vaporization has also been used to resect small (T1/T2)
oral squamous cell carcinoma (OSCC), with results comparable to
those of surgery (Jerjes et al., 2011).
We retrospectively reviewed the results for a sample of patients
with oral leukoplakia treated with CO2 laser. Our main objective
was to evaluate treatment results, and our secondary objectives
were to determine the recurrence and malignant transformation
rates, to quantify complications associated with the procedure, and
to suggest a follow-up protocol.
2. Material and methods
A total of 65 patients were treated with CO2 laser vaporization
between January 2010 and April 2013. Medical records were
reviewed to evaluate demographic data, history of OSCC, location of
the lesion, histological malignancy grade, complications, re-
currences, and malignant transformation.
A histopathological diagnosis of leukoplakiawas obtained prior
to surgery on the basis of an incisional biopsy. All surgical pro-
cedures were performed under local anesthesia via local tissue
inﬁltration with articaine hydrochloride (72.0 mg) and epineph-
rine (0.018 mg). A Lumenis CO2 laser (10.6-mmwavelength) set up
in superpulse focused mode was used for vaporization (15W). The
mucosaehandpiece distance was 15e20 mm, handpiece focus
length was 125 mm, laser exposure was 20 s, spot diameter was
0.3 mm, and ﬂuence energy was 4,244 J/cm2. Depending on the
location of the lesion, buccal mucosa, lip, or tongue were sepa-
rated using gauze. The laser was tested on a moist gauze prior to
each surgery, and the mandatory special mask and glasses were
worn. A high-potency vacuum device was used to aspirate the
laser plume. Clinical pictures of the oral leukoplakia were taken in
the operation room and during follow-up. Prescribed for post-
operative care were 0.12% chlorhexidine gel and 600 mg of
ibuprofen every 8 h. Follow-up examinations were performed
according to our protocol on day 7 after surgery, every 3 months in
the ﬁrst year, every 6 months in the second year, and annually
thereafter.
2.1. Statistical analysis
Demographic and clinical variables were analyzed descriptively,
and categorical variables were reported as frequencies and per-
centages. The ShapiroeWilks statistic was used to test the distri-
bution of continuous variables, described as mean (standard
deviation) if they followed a normal distribution or as median
(interquartile range) otherwise. KaplaneMeier curves with log-
rank tests were used to assess time to recurrence and malignant
transformation according to the different clinical characteristics of
interest. Univariate Cox regression was used to identify risk factors
for recurrence and malignant transformation, calculating the haz-
ard ratio (HR) and establishing a 95% conﬁdence interval (95% CI). A
p value of less than 0.05 in these tests was considered to indicate
statistical signiﬁcance. SPSS 18.0 forWindows (SPSS Inc, Chicago, IL,
USA) was used for all statistical analyses.
3. Results
The study cohort consisted of 65 patients who underwent
vaporization at our center between January 2010 and April 2013.
The median follow-up was 15.0 (0.3e38.7) months. Demographic
and clinical characteristics of the patients are summarized inTable 1.
Just under half the patients weremale (n¼ 32, 49.2%), patientmean
age at surgery was 66.2 (13.1) years, and 15 patients (23.1%) had a
history of OSCC. Primary sites were mainly identiﬁed in the tongue
(n ¼ 21, 32.3%) and the gingiva (n ¼ 19, 29.2%). The initial biopsy
showedmild/moderate dysplasia in almost half the patients (n¼ 29,
44.6%) and hyperplasia without dysplasia in around a third of pa-
tients (n¼ 21, 32.3%). Half the gingiva lesions presented nodysplasia
(n ¼ 10/19, 52.6%). The procedure-related complications rate was
7.7% (n ¼ 5), with all complications associated with postoperative
pain that required nonsteroidal anti-inﬂammatory drug treatment.
During follow-up, 22 patients (33.8%) had a recurrence, repre-
senting an annual rate of 35.3% (95% CI ¼ 22.1e53.4). The main
characteristics of this group and potential risk factors for recur-
rence are summarized in Table 2. No differences were observed by
gender, smoking and alcohol consumption, number of lesions,
histological grade, or previous history of OSCC. Lesion location in
the gingiva as opposed to the tongue was found to be a risk factor.
KaplaneMeier curves for time to recurrence (Fig. 1) showed
differences only for lesion location in the gingiva compared to the
tongue (log rank, p ¼ 0.032).
During follow-up, 10 patients (15.4%) presented with malignant
transformation, representing an annual rate of 12.3% (95%
CI ¼ 6.0e22.7). The main characteristics of this group and potential
risk factors formalignant transformation are summarized inTable 3.
No differences were observed by gender, smoking and alcohol
consumption, number of lesions, or histological grade. Lesion
location in the gingiva as opposed to the tongue a history of OSCC
showed a tendency to be risk factors for malignant transformation.
4. Discussion
Early detection of premalignant and malignant intraoral lesions
improves long-term survival rates and minimizes treatment
Table 1
Demographic and clinical data.
Total
n (%)
(n ¼ 65)
Recurrence
n (%)
(n ¼ 22)
Malignant
transformation
n (%)
(n ¼ 10)
Mean age (y) 66.2 66.6 66.6
Male 32 (49.2) 9 (40.9) 5 (50)
Smokers 36 (55.4) 13 (59.1) 4 (40)
Alcohol consumers 25 (38.5) 9 (40.9) 5 (50)
Leukoplakia location
Tongue 21 (32.3) 7 (31.8) 4 (40)
Gingiva 19 (29.2) 10 (45.5) 3 (30)
Lip 5 (7.7) 2 (9.1) e
Buccal mucosa 10 (15.4) 1 (4.5) 2 (20)
Floor of mouth 4 (6.2) 1 (4.5) 1 (10)
Retromolar trigone 3 (4.6) 1 (4.5) e
Palate 3 (4.6) 0 e
Multiple sites 15 (23.1) 7 (31.8) 2 (20)
Dysplasia grade
0 21 (32.3) 7 (31.8) 2 (20)
1 29 (44.6) 12 (54.5) 4 (40)
2 8 (12.3) 2 (9.1) 2 (20)
3 7 (10.8) 1 (4.5) 2 (20)
OSCC history 15 (23.1) 7 (31.8) 6 (60)
Complications 5 (7.7) 3 (13.6) 2 (20)
Re-vaporization 20 (30.8) 20 (90.9) e
Malignant transformation 10 (15.4) 5 (22.7) e
A. Mogedas-Vegara et al. / Journal of Cranio-Maxillo-Facial Surgery xxx (2015) 1e52
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
YJCMS1994_proof ■ 7 April 2015 ■ 2/5
Please cite this article in press as: Mogedas-Vegara A, et al., The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65
patients, Journal of Cranio-Maxillo-Facial Surgery (2015), http://dx.doi.org/10.1016/j.jcms.2015.03.011
requirements (Deppe et al., 2012; Ho et al., 2013). Diagnoses of
leukoplakia can be classiﬁed according to levels of certainty (C-
factor), in clinical terms (C1eC2) or in pathological terms (C3eC4).
In this study we used a C3 factor, based on evidence obtained by the
elimination of suspected etiologic factors during a follow-up period
of 2e4 weeks and the absence of any suspected etiological factors,
complemented by incisional biopsy (Van derWaal, 2009). Although
the histopathological diagnosis was made by incisional biopsy, a
recent study has shown that there may be discrepancies between
the results for incisional biopsy compared to excisional biopsy,
producing a potential underdiagnosis of dysplastic lesions by 28%
andmasking an OSCC diagnosis in 9% of cases (Goodson et al., 2012;
Brouns et al., 2014). Differential diagnoses for white lesions of the
oral cavity are candidiasis, lupus erythematosus, lichen planus,
Table 2
Recurrence group characteristics.
Characteristic n (%) HR (95% CI)
Gender
Male 9/32 (28.1) 1.00
Female 13/33 (39.4) 1.24 (0.53e2.91)
Tobacco
Nonuse 9/29 (31.0) 1.00
Use 13/36 (36.1) 1.37 (0.59e3.21)
Alcohol
Nonuse 13/40 (32.5) 1.00
Use 9/25 (36.0) 1.17 (0.50e2.73)
Leukoplakia location
Other 5/25 (20.0) e
Tongue 7/21 (33.3) 1.00
Gingiva 10/19 (52.6) 2.84 (1.07e7.54)
Multiple locations
No 15/50 (30.0) 1.00
Yes 7/15 (46.7) 1.34 (0.54e3.29)
Dysplasia grade
0 7/21 (33.3) 2.84 (0.73e11.01)
1 12/29 (41.4) 44.44 (0.69e8.65)
$2 3/15 (20.0) 1.00
OSCC history
No 15/50 (30) 1.00
Yes 7/15 (16.7) 0.74 (0.30e1.83)
CI, conﬁdence interval; HR, hazard ratio.
Fig. 1. KaplaneMeier curves for time to recurrence showed differences only for the location of the lesion in the gingiva compared to the location on the tongue (log rank p¼ 0.032).
Table 3
Malignant transformation group characteristics.
Characteristic n (%) HR (95% CI)
Gender
Male 5/32 (15.6) 1.00
Female 5/33 (15.1) 1.52 (0.40e5.71)
Tobacco
Nonuse 6/29 (20.6) 1.00
Use 4/36 (11.1) 0.42 (0.11e1.52)
Alcohol
Nonuse 5/40 (12.5) 1.00
Use 5/25 (20.0) 1.77 (0.47e6.63)
Leukoplakia location
Other 3/25 (12.0) e
Tongue 4/21 (19.0) 1.00
Gingiva 3/19 (15.7) 1.61 (0.35e7.44)
Multiple locations
No 8/50 (16.0) 1.00
Yes 2/15 (13.3) 0.27 (0.34e2.22)
Dysplasia grade
0 2/21 (9.5) 0.30 (0.05e1.81)
1 4/29 (13.7) 0.33(0.78e1.4)
$2 4/15 (26.6) 1.00
OSCC history
No 4/50 (8) 1.00
Yes 6/15 (40%) 2.25 (0.62e8.10)
CI, conﬁdence interval; HR, hazard ratio.
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traumatic irritative lesions, aspirin-induced necrosis, syphilis,
papilloma, hereditary white lesions and geographic tongue
(Escribano-Bermejos and Bascones-Martínez, 2009; Brouns et al.,
2013b). The most commonly reported location of leukoplakia is
the lateral border of the tongue (Escribano-Bermejos and Bascones-
Martínez, 2009; Brouns et al., 2013a, 2014). In our cohort, the
tongue was also the most frequent location (n ¼ 21, 32.3%).
Although there is no scientiﬁc evidence that any treatment
prevents the onset of OSCC, it is safe to treat and successively
follow up leukoplakia whether or not dysplasia is present
(Chandu and Smith, 2005; Van derWaal, 2009; Santos et al., 2010;
Jerjes et al., 2011; Yang et al., 2011; Goodson et al., 2012; Ho et al.,
2013). Dysplasia severity is the most common risk factor associ-
ated with malignant transformation (Chandu and Smith, 2005;
Goodson et al., 2012); however, we could not demonstrate this
fact in our sample. No randomized trials are reported in the
literature that compare surgery with CO2 laser in terms of local
recurrence and malignant transformation (Brouns et al., 2013a).
The recurrence and malignant transformation rates for our sam-
ple were 33.8% and 15.4%, respectively, comparable with those
found in literature (7.7%e40% for recurrences and 0.83%e14% for
malignant transformation; Table 4) (Chiesa et al., 1993; Schoelch
et al., 1999; Thomson, 2002; Thomson and Wylie, 2002; Chandu
and Smith, 2005; Van der Hem et al., 2005; Yang et al., 2011;
Deppe et al., 2012; Jerjes et al., 2012; Brouns et al., 2013a, 2014).
It is currently unknown whether resection margin width is a
factor in recurrence, and no molecular marker currently exists
that determines this risk. No uniform criteria are available,
although it is recommended to respect a few millimeters to the
margin; nonetheless, it has been shown that there may be
changes in the cell nucleus beyond where the leukoplakia is
visible (Van der Waal, 2009; Brouns et al., 2014). Slaughter et al.
ﬁrst used the term “ﬁeld of cancerization” in 1953 (Slaughter
et al., 1953), on realizing that patients with OSCC frequently
presented with premalignant lesions and often had multiple
primary tumors in the upper aerodigestive tract (UADT), and
hypothesized that the UADT epithelium showed a higher pro-
portion of premalignant lesions than other tissues because of
multiple genetic abnormalities in the whole tissue region
(Thomson, 2002; Thomson and Wylie, 2002; Feller and Lemmer,
2011).
In our sample of 65 patients, of 15 (23.1%) with a history of OSCC,
7 had recurrences and 6 presented with malignant transformation.
For patients with a previous history of OSCC, no statistically sig-
niﬁcant differences were observed with the occurrence of re-
currences, whereas a trend was evident for the case of malignant
transformation (2.25 [0.62e8.10]).
Malignant transformation of leukoplakia is independent of
treatment, and it seems that areas with molecular preneoplastic
changes may lead to multiple lesions (Yang et al., 2011; Ho et al.,
2013; Kumar et al., 2013; L!opez-Jornet and Camacho-Alonso,
2013). Despite advances in molecular biology, there are currently
no markers to predict malignant transformation of oral leukopla-
kia; hence, several authors recommend excision of any leukoplakia
whether or not dysplasia is present (van der Waal., 2009; Ho et al.,
2013; Kumar et al., 2013; Brouns et al., 2014).
Although different laser types have been used in the treatment
of oral leukoplakia, including neodymium:yttrium-aluminium
garnet (Nd:YAG), potassium-titanyl-phosphate (KTP) and argon
lasers, the CO2 laser is the most frequently used (Novakovic et al.,
2011).
Nd:YAG lasers (wavelength 1,064 nm) are the second most
popular lasers for leukoplakia vaporization and intraoral tumor
excision after the CO2 lasers. They are recommended for patients
with hemorrhage risk due to their higher potency and deep
penetration, but higher postoperative pain rates have been re-
ported for Nd:YAG lasers compared with CO2 lasers (Ishii et al.,
2003). Vivek et al. (2008) reported recurrence and a malignant
transformation rate of 10.71% after 3 years of follow-up of a group
of 28 patients treated with Nd:YAG laser. White et al. reported a
recurrence rate of 27.2% (6/22) for the YAG laser and 23.5% (4/17) for
the CO2 laser (White et al., 1998).
KTP laser penetrates deeper into the tissue (wavelength
532 nm) and is frequently used to coagulate vascular lesions. Lim
et al. compared KTP laser and CO2 laser for leukoplakia ablation,
reporting recurrence rate of 25% and 39.5%, respectively, and ma-
lignant transformation rates of 13.3% and 6.6%, respectively (Ishii
et al., 2003; Lim et al., 2010).
Currently there is no evidence about the possible value of
follow-up. However, due to the high recurrence rate, we recom-
mend follow-up every 3 months in the ﬁrst year, every 6 months in
the second year, and annually for life thereafter (Van der Waal,
2009). Clinical examination and photographs are essential to
observe the evolution of lesions. New biopsies are mandatory if
changes are detected on inspection or palpation (L!opez-Jornet and
Camacho-Alonso, 2013).
5. Conclusion
The use of CO2 laser for the treatment of oral leukoplakia is a
reliable, reproducible technique associated with a very low com-
plications rate. Recurrence and malignancy rates for our cohort
(33.8% and 15.4%, respectively) were similar to rates (7.7% and 40%
for recurrences and 0.83% and 14% for malignancies) reported for
other studies (Chiesa et al., 1993; Schoelch et al., 1999; Thomson,
2002; Thomson and Wylie, 2002; Chandu and Smith, 2005; Van
der Hem et al., 2005; Yang et al., 2011; Deppe et al., 2012; Jerjes
et al., 2012; Brouns et al., 2013a, 2014). We would recommend
close lifelong follow-up with photographs, along with new biopsies
when changes are detected. Future development of molecular
markers may help to determine the risk of malignant leukoplakia
transformation and to choose the best treatment. Q2
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Table 4
Recurrence and malignant transformation rates.
First author, year Patients
(n)
Lesions Recurrence Malignant
transformation
Follow-up
Brouns
2013
35 35 40% 14% 61.5 mo
Jerjes
2012
77 123 19.5% 10.4% 6.4 y
Deppe
2012
119 120 23.3% 0.83% 75 mo
Yang
2011
114 114 17.5% 11.4% 3.4 y
Van der Hem
2005
200 282 9.9% 1.1% 52 mo
Chandu
2005
43 73 28.9% 7.3% 47.2 mo
Thomson & Wylie
2002
57 55 24% 7% 4 y
Schoelch 1999 55 55 38.18% 9.09% 32 mo
Chiesa
1993
167 167 34.73% 3% 5 y
Horch
1986
50 50 22% NA 37 mo
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